Introduction
============

*Clostridioides difficile* is one of the most common human nosocomial pathogens and causes antibiotic-associated diarrhea leading sometimes to severe pseudomembranous colitis ([@B20]; [@B36]). The main virulence factors are *C. difficile* toxin A (TcdA) and toxin B (TcdB) ([@B17]). They both belong to the clostridial glucosylating toxins (CGT) that inactivate small GTPases by transferring a glucose moiety to a highly conserved threonine residue (Thr-35 in Rho and Thr-37 in Rac/Cdc42) ([@B18]), while TcdB is up to 1,000 times more potent than TcdA ([@B2]). In case of TcdB Rho, Rac, and Cdc42 are glucosylated causing a perturbed downstream signaling of the affected small GTPases ([@B19]; [@B39]; [@B12]). This leads initially to a rearrangement of the cytoskeleton and cell cycle arrest (cytopathic effect) ([@B30]; [@B13]) and finally to apoptosis (cytotoxic effect) ([@B23]). Recently, it has been shown that high concentrations of TcdB, but not TcdA, have an additional effect causing necrotic cell death termed pyknosis ([@B10]; [@B38]; [@B3]; [@B11]). This is manifested in morphological changes such as chromatin condensation, ballooning of the plasma membrane and loss of membrane integrity. Interestingly, this effect is also triggered by the glucosyltransferase-deficient mutant TcdB~NXN~ and is therefore independent of small GTPase glucosylation ([@B38]). It has been suggested that ROS production and involvement of the NADPH oxidase complex are responsible for this effect. However, exact mechanisms of both effects -- glucosyltransferase-dependent and independent -- are still mostly unknown. Recently, several proteome studies have been conducted to investigate the impact on the proteome and to elucidate the affected downstream signaling pathways by TcdA and TcdB treatment with variating toxin concentrations ([@B39]; [@B15]; [@B16]; [@B9]). Both toxins exhibit similar effects on the proteome of human epithelial cells when using moderate toxin concentrations. Especially proteins associated with cytoskeleton organization, signaling, cell--cell contact and cell proliferation are significantly altered. Interestingly, these protein groups were also affected by inducing pyknosis with high TcdB~NXN~ concentrations, except proteins involved in GTPase-related signaling.

In this study a comprehensive phosphoproteome study was conducted to further investigate the involved signaling pathways which are altered after TcdB and TcdB~NXN~ treatment ([@B33]). Pyknosis-inducing conditions and the human epithelial cell line HEp-2 were chosen, in order to cover the glucosyltransferase-independent effect. With the use of SCX chromatography and IMAC and TiO~2~ phosphopeptide enrichment techniques in total more than 1,000 significantly altered phosphosites were identified which alterations shed more light on intracellular regulatory processes upon toxin treatment.

Materials and Methods {#s1}
=====================

Cultivation of HEp-2 Cells and SILAC Labeling
---------------------------------------------

The human epithelial cell line HEp-2 was cultured in 75 cm^2^ flasks in a humidified 5% CO~2~ atmosphere at 37°C and 95% humidity. Cells were cultivated in Minimum Essential Media (MEM) without arginine and lysine (Thermo Fisher Scientific, United States). The media was supplemented with 10% dialyzed bovine fetal calf serum (Silantes, Germany), 100 U/ml penicillin, 0.1 mg/ml streptomycin (Merck, Germany) and 0.4 mM L-proline (Sigma, Germany) in order to avoid arginine-proline conversion ([@B21]). For the metabolic labeling 0.6/0.4 mM Arg-0/Lys-0 (light), Arg-6/Lys-4 (medium), or Arg-10/Lys-8 (heavy) (Silantes, Germany) were added according to SILAC protocol ([@B27]). Complete incorporation of stable isotope labeled amino acids was checked prior to experiments by LC-MS. Cells were passaged every 3--4 days at a 1:5 split ratio.

Treatment of HEp-2 Cells and Sample Preparation
-----------------------------------------------

At a confluency of 75% the differently labeled HEp-2 cells were treated with 2 nM TcdB or TcdB~NXN~ for 8 h. Recombinant toxins were generated using the *Bacillus megaterium* expression system as previously described ([@B26]). Untreated cells cultured in SILAC-media were used as control. All experiments were carried out in triplicates including a label switch. Changes in cell morphology were documented by phase contrast microscopy (Zeiss, Germany). After treatment, cells were washed twice with ice cold PBS and subsequently harvested by scraping cells and dissolved in lysis buffer containing 50 mM ammonium bicarbonate (pH 8.0), 8 M Urea, 1 mM sodium ortho-vanadate, complete EDTA-free protease inhibitor cocktail (Roche) and phosSTOP phosphatase inhibitor cocktail (Roche). Cells were homogenized on ice by sonication and cell debris was removed by centrifugation at 16,000 *g* for 20 min at 4°C and total protein concentrations was determined using a Lowry assay (Bio-Rad). Equal amounts (1.3 mg) of differently labeled and treated lysates were combined as already described ([@B39]; [@B16]).

Protein Digestion and Fractionation by SCX
------------------------------------------

Proteins were reduced with dithiothreitol (DTT) (5 mM) for 1h at 37°C and subsequently alkylated with iodoacetamide IAA (10 mM) in the dark at room temperature for 30 min. Alkylation was stopped by adding DTT at a final concentration of 5 mM. Lysates were diluted with 50 mM ABC to a final urea concentration below 4 M. Proteins first were digested with Lys-C (Wako) at a 1:150 enzyme/protein ratio for 4 h at 37°C and then trypsin (1:80; Promega) was added followed by an overnight incubation at 37°C. Digestion was stopped by acidification with TFA to a final concentration of 1%. Peptide solution was desalted using Sep-Pak tC18 cartridges (Waters) according to the manufacturer's protocol.

Dried peptides were dissolved in SCX Buffer A (7 mM KH~2~PO~4~, pH 2.65, 30% ACN) and separated by strong cation exchange (SCX) using an Agilent 1200 HPLC equipped with a PolySULFOETHYL A column (250 mm × 9.4 mm; 5 μm beads, pore size 200Å) (259-SE0502, PolyLC Inc.). Chromatography was performed by increasing SCX Buffer B concentration (7 mM KH~2~PO~4~, 350 mM KCl, pH 2.65, 30% ACN) from 1--30% over 40 min at a flow rate of 2 ml/min. Twelve 5-min fractions were collected over the full run, lyophilized and subsequently desalted using Sep-Pak tC18 cartridges (Waters). Fractions 1/2, 3/4, and 11/12 were pooled for phosphopeptide enrichment resulting in a total of 9 fractions.

Phosphopeptide Enrichment
-------------------------

A 2D affinity chromatography was conducted for phosphopeptide enrichment for each of the 9 fractions. In the first step peptides were subjected to an immobilized metal affinity chromatography using a Fe-NTA phosphopeptide enrichment kit according to the manufacturer's protocol (\#88300, Thermo Fisher Scientific). Eluted phosphopeptides were acidified by TFA to final concentration of 2.5% and dried by vacuum centrifugation. All flow-troughs after sample loading were pooled, dried by vacuum centrifugation and stored for subsequent enrichment step by metal oxide affinity chromatography (MOAC) using the TiO~2~ phosphopeptide enrichment spin tips (\#88303, Thermo Fisher Scientific). Spin tips were equilibrated by washing with Buffer A (80% ACN/0.4% TFA) first and then with Buffer B (57% ACN/0.3% TFA/25% lactic acid). Peptides were suspended in Buffer B and applied to the spin tips. After reapplying samples, spin tips were again washed with Buffer B and three times with Buffer A before peptides were eluted with 1.5% NH~4~OH first and then with 5% pyrrolidine. Eluted samples were acidified with TFA to a final concentration of 1.25% and dried by vacuum centrifugation. All IMAC and TiO~2~ elution fractions were cleaned up prior to MS analysis using graphite spin columns (\#88302, Thermo Fisher Scientific) according to the manufacturer's protocol.

Liquid Chromatography Mass Spectrometry (LC-MS)
-----------------------------------------------

Dried phosphopeptides were reconstituted in 2% ACN/0.1% TFA and analyzed by an Obritrap Velos mass spectrometer connected to an Ultimate 3000 RSLC nanoflow system (Thermo Fisher Scientific). Samples were loaded on a trap column (2 cm length, 75 μm ID, 3 μm C18 particles) at a flow rate of 6 μl/min of 0.1% TFA for 5 min. The trap column was switched in line with the analytical column (Acclaim PepMap, Thermo Fisher Scientific, 50 cm length, 75 μm ID, 2 μm C18 particles,) and peptides were eluted at a flow rate of 250 nl/min and at 45°C column temperature by an increasing multistep linear acetonitril gradient from 4 to 25% in 105 min and from 25 to 50% in the following 35 min. The column outlet was directly connected to the nano electrospray source of the mass spectrometer and peptides were ionized with a spray voltage of 1.35 kV using metal-coated fused silica emitter.

The Orbitrap Velos mass spectrometer was operated in data-dependent acquisition mode recording survey scans in the orbitrap mass analyzer with a mass range from 300 to 1600 at a resolution of 60,000 at m/z 400. The five most intense precursors with a charge state of +2 or higher were selected for CID fragmentation with a normalized collision energy of 38 using multi-stage activation for the neutral loss masses of phosphoric acid and MS/MS spectra were acquired in the linear ion trap mass analyzer. Dynamic exclusion duration was set to 30 s.

Data Processing
---------------

Raw data were processed with MaxQuant software (version 1.5.3.30) ([@B4]) and peptides were identified by searching against all human entries of the UniProtKB/Swiss-Prot database using the Andromeda search engine ([@B6]). Propionamidation (C) was set as fixed modification and a maximum of two missed cleavages was allowed. Phosphorylation (S/T/Y), oxidation (M), deamidation (N/Q) and acetylation (protein N-terminal) were set as variable modifications. A false discovery rate of 0.01 on peptide and protein level was used for identification and "re-quantify" and "match between runs" options were checked. For quantification a minimum ratio count of 1 was used and peptides had to be identified in at least 2 replicates for statistical analysis. Data were analyzed and visualized with the software tools Perseus (version 1.5.2.6) ([@B5]; [@B35]) and Cytoscape (version 3.4) [@B31]). Two sided on-sample Student's *t*-test was applied for the comparison between TcdB vs. control and TcdB~NXN~ vs. control.

Results
=======

Altered Morphology by TcdB and TcdB~NXN~ Treatment
--------------------------------------------------

HEp-2 cells were used to elucidate the impact of TcdB and TcdB~NXN~ on the phosphorylation status of cellular proteins designated as phosphoproteome. According to previous proteome studies cells were treated with a high toxin concentration of 2 nM for 8 h to induce both, cell rounding and the pyknotic phenotype. After TcdB treatment most cells exhibited the typical cell rounding morphology (Figure [1](#F1){ref-type="fig"}) and about 20% of the cells showed the pyknotic morphology. The glucosyltransferase-deficient mutant TcdB~NXN~ only revealed the pyknotic phenotype for almost all cells. No morphological changes were observed in the control.

![Morphological changes after TcdB or TcdB~NXN~ treatment. Subconfluent HEp-2 cells were treated either with 2 nM TcdB or 2 nM TcdB~NXN~ for 8 h. Control cells were not treated and illustrate normal morphology. TcdB treatment led to typical rounding of most cells and also some pyknotic cells could be observed by phase-contrast microscopy; whereas in consequence of TcdB~NXN~ treatment all cells exhibited only pyknotic morphology, which was manifested by blistering and chromatin condensation.](fmicb-09-03083-g001){#F1}

Quantitative Phosphoproteome Analysis After TcdB or TcdB~NXN~ Treatment
-----------------------------------------------------------------------

The phosphoproteome was analyzed by using a SILAC triplex shotgun approach in combination with SCX and phosphopeptide enrichment by IMAC and TiO~2~ prior to MS analysis. With this technique in total 3,256 protein groups were identified by sequence identification of 12,447 peptides (Supplementary Tables [1](#SM1){ref-type="supplementary-material"}, [2](#SM2){ref-type="supplementary-material"}). Nearly 50% of the identified proteins possessed at least one phosphorylation site (Figure [2A](#F2){ref-type="fig"}). A phosphorylation site was determined for 5,855 peptides (Figure [2B](#F2){ref-type="fig"}). Out of these phosphosites 73.2% were identified by IMAC and 26.8% by TiO~2~ enrichment (Figure [2C](#F2){ref-type="fig"}). Around 82.6% of the identified phosphopeptides were monophosphorylated, while 16.3% were double phosphorylated and about 1% was multiphosphorylated (Figure [2D](#F2){ref-type="fig"}). About 80% of the phosphate moieties were located at serine residues, 19% at threonine residues and only less than 1% at tyrosine residues (Figure [2E](#F2){ref-type="fig"}). The analysis of phosphorylation motifs of all regulated phosphosites revealed the consensus sequence R/X-X-S-P and S-P for phosphoserine and T-P for phosphothreonine (data not shown).

![Comprehensive characterization of the obtained dataset. Donut charts illustrating the percentage of identified phosphorylated and non-phosphorylated proteins **(A)** and peptides **(B)**. Red areas represent phosphorylated peptides and proteins, blue areas not phosphorylated proteins and peptides. **(C)** Total phosphopeptides have been enriched using IMAC (blue) or TiO2 (red) techniques. **(D)** Identified phosphopeptides contained either one (blue), two (red), or three or more (green) phosphor groups. **(E)** Phosphorylation was detected at serine (blue), threonine (red), and tyrosine (green) residues.](fmicb-09-03083-g002){#F2}

The quality of data was supported by a principle component analysis (PCA) of all phosphopeptides identified in the 3 replicates (Figure [3A](#F3){ref-type="fig"}). Each possible comparison (TcdB/Control; TcdB~NXN~/Control; TcdB/TcdB~NXN~) clustered properly showing the reproducibility of the fractionation and enrichment method.

![Data reproducibility and phosphopeptide enrichment method analysis. **(A)** Principal component analysis of SILAC labeled replicates illustrating the workflow reproducibility. **(B)** Histogram showing the distribution of identified phosphorylated and non-phosphorylated peptides and the percentage of enrichment across each fraction of SCX chromatography.](fmicb-09-03083-g003){#F3}

All SCX fractions contributed to the total quantity of identified phosphopeptides (Figure [3B](#F3){ref-type="fig"}). Especially in the first three fractions more than 50% of the identified peptides contained a phosphate moiety. In contrast, the middle fractions contained mainly non-phosphorylated peptides, while the amount of phosphorylated peptides remained comparatively constant across all fractions. The number of identified peptides was highest in fraction 5 and declined continuously to fraction 9.

The comparison of TcdB vs. control revealed in total 4,336 class-I-phosphosites with a localization probability higher than 75%. The number of identified phosphosites was 3,697 for replicate 1, 2,914 for replicate 2 and 3,112 for replicate 3 (Figure [4A](#F4){ref-type="fig"}). 2,197 phosphosites were identified in all the replicates, resulting in a reproducibility of 50.7%. The comparison of TcdB~NXN~ vs. control resulted in very similar numbers (data not shown). Phosphosites had to be identified in at least two replicates in order to be considered for quantification.

![Phosphoproteome analysis of TcdB or TcdB~NXN~ treated HEp-2 cells. **(A)** Venn diagram of all identified phosphosites with a localization probability higher than 75% for all three replicates. **(B)** Venn diagram of all significantly regulated phosphosites as consequence of TcdB or TcdB~NXN~ treatment. Volcano plots of TcdB **(C)** or TcdB~NXN~ **(D)** treated vs. untreated control cells. Negative log~10~ *p*-values were plotted against the log~2~ phosphosite ratios illustrating the significantly regulated sites (red dots: down-regulation; green dots: up-regulation) with a minimum fold change of 2 and a *p*-value less than 0.05.](fmicb-09-03083-g004){#F4}

TcdB treatment for 8 h with 2 nM led in total to 1,012 significantly altered phosphosites, whereas TcdB~NXN~ treatment resulted in 686 changed phosphosites. The overlap was 401 phosphosites, while 611 and 285 were altered exclusively by TcdB or TcdB~NXN~, respectively (Figure [4B](#F4){ref-type="fig"}). When taking only phosphosites with a biological relevance with a fold change of at least 2 into account, 177 up-regulated and 141 down-regulated sites after TcdB treatment were obtained. In case of TcdB~NXN~ 86 phosphosites were up-regulated and 53 down-regulated. It is noticeable that more phosphosites exhibited a stronger phosphorylation than vice versa indicating a general stronger activation of phosphoproteins (Figures [4C,D](#F4){ref-type="fig"}).

The 10 most up- and down-regulated phosphosites with the corresponding proteins and genes are presented in Table [1](#T1){ref-type="table"} for TcdB and Table [2](#T2){ref-type="table"} for TcdB~NXN~ treatment. It can be noted that the regulation factors were much higher as a consequence of TcdB treatment than after TcdB~NXN~ treatment. The highest up-regulated phosphosite in case of TcdB was S-63 of the transcription factor AP-1 with a fold change (fc) of 18.1, while TcdB~NXN~ treatment led to an up-regulation of phosphosite at S-208 of Serine/arginine-rich splicing factor 2 (fc = 9.6). The most down-regulated phosphosites was S-5448 of neuroblast differentiation-associated protein AHNAK (fc = −23.6) in case of TcdB and a doubly phosphorylated peptide of 40S ribosomal protein S6 (S-236; T-241) with a fold change of −5.2 after TcdB~NXN~ treatment. Interestingly, 4 more phosphorylated peptides of 40S ribosomal protein S6 were highly down-regulated. When looking at TcdB it is noticeable that many GTPase effector or regulation proteins and transcription factors enclose the most strongly regulated phosphopeptides.

###### 

Top 10 up- and down-regulated phosphosites after 8 h treatment with TcdB.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Uniprot ID   Gene name   Protein name                                          Peptide sequence                  log~2~ Ratio TcdB/control   *p*-Value   Amino acid   Peptide score
  ------------ ----------- ----------------------------------------------------- --------------------------------- --------------------------- ----------- ------------ ---------------
  P05412       JUN         Transcription factor AP-1                             NSDLLT**[S]{.ul}**PDVGLLK         4.18                        2.05E-02    S-63         200.33

  M0QZ04       ZFP36       Tristetraprolin                                       ST**[S]{.ul}**LVEGR               3.85                        4.77E-02    S-67         123.79

  P05412       JUN         Transcription factor AP-1                             LA**[S]{.ul}**PELER               3.67                        3.32E-03    S-73         111.27

  Q9NQW6       ANLN        Actin-binding protein anillin                         NKA**[S]{.ul}**PQSEFMPSK          3.52                        2.24E-04    S-792        127.49

  Q09666       AHNAK       Neuroblast differentiation-associated protein AHNAK   LK**[S]{.ul}**EDGVEGDLGETQSR      3.40                        3.32E-03    S-135        255.63

  E5RJU9       MTDH        Protein LYRIC                                         LSSQI**[S]{.ul}**AGEEK            3.26                        8.28E-04    S-275        117.2

  G3V1T9       RBM7        RNA-binding protein 7                                 SF**[S]{.ul}**SPENFQR             3.19                        9.30E-03    S-16         125.36

  P05412       JUN         Transcription factor AP-1                             LQALKEEPQTVP\                     3.02                        9.36E-03    S-243        83.944
                                                                                 EMPGETPPL**[S]{.ul}**PIDMESQER                                                         

  K7EMZ9       LSM14A      Protein LSM14 homolog A                               TQL**[S]{.ul}**QAEVHK             2.89                        1.18E-02    S-173        96.135

  V9GYM8       ARHGEF2     Rho guanine nucleotide exchange factor 2              SE**[S]{.ul}**LESPRGER            2.88                        1.31E-03    S-690        145.81

                                                                                                                                                                        

  Q09666       AHNAK       Neuroblast differentiation-associated protein AHNAK   I**[S]{.ul}**APNVDFNLEGPK         −4.56                       2.13E-02    S-5448       188.9

  Q9H7D0       DOCK5       Dedicator of cytokinesis protein 5                    **[S]{.ul}**LQLMDNR               −3.92                       4.44E-03    S-1766       130.1

  Q9H3Q1       CDC42EP4    Cdc42 effector protein 4                              AGEPDGE**[S]{.ul}**LDEQPSSSSSK    −3.79                       4.23E-02    S-64         192.16

  Q9H2G2       SLK         STE20-like serine/threonine-protein kinase            RA**[S]{.ul}**SDLSIASSEEDK        −3.43                       3.03E-02    S-340        228.65

  Q5VZK9       LRRC16A     Leucine-rich repeat-containing protein 16A            RS**[S]{.ul}**GFISELPSEEGK        −3.20                       2.47E-02    S-968        216.75

  Q9Y446       PKP3        Plakophilin-3                                         **[T]{.ul}**LQRLSSGFDDIDLPSAVK    −3.16                       3.50E-02    T-308        127.41

  Q13177       PAK2        Serine/threonine-protein kinase PAK 2                 YL**[S]{.ul}**FTPPEK              −3.04                       4.94E-03    S-141        166.29

  Q9Y5K6       CD2AP       CD2-associated protein                                **[S]{.ul}**VDFDSLTVR             −2.78                       4.62E-03    S-458        177.1

  Q00587       CDC42EP1    Cdc42 effector protein 1                              NAI**[S]{.ul}**LPQLNQAAYDSLVVGK   −2.68                       8.80E-06    S-121        249.25

  P46937       YAP1        Transcriptional coactivator YAP1                      ISQ**[S]{.ul}**APVK               −2.67                       3.81E-04    S-276        112.64
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Discussion
==========

For the first time the effects of TcdB or glucosyltransferase deficient mutant TcdB~NXN~ on the phosphoproteome of target cells were examined. *C. difficile* toxins inhibit small GTPases of the Rho- and Ras-family by glucosylation leading to perturbation of affected signaling pathways and subsequent actin cytoskeleton breakdown. Since protein phosphorylation plays an important role in signaling pathways a phosphoproteome approach has been chosen to reveal further insights into GTPase down-stream processes induced by *C. difficile* toxins ([@B33]). A SILAC approach was chosen to precisely quantify the toxin-induced effects in HEp-2 cells which show a clear pyknotic phenotype. Phosphopeptides were enriched by a combination of IMAC and TiO~2~ materials prior to LC-MS shotgun analysis which is an approved strategy to detect as much phosphopeptides as possible.

With the chosen setup 4,197 phosphorylated peptides containing 5,855 phosphosites were identified. Of these phosphosites 4,336 had a localization probability higher than 75% and therefore were qualified for quantification (Figure [2](#F2){ref-type="fig"}). Overall 1,297 phosphosites were significantly altered due to TcdB or TcdB~NXN~ treatment (2 nM for 8 h) (Figure [4](#F4){ref-type="fig"}). Interestingly, the glucosyltransferase deficient TcdB~NXN~ had a strong impact on the phosphoproteome. These effects should be independent from inactivation of small GTPases by glucosylation. In previous proteome studies a strong input on proteome homeostasis has been observed for TcdB~NXN~ treated cells indicating glucosyltranferase-independent activities of TcdB ([@B9]). Glucosyltransferase active TcdB induces, as expected, cell rounding due to cytoskeleton rearrangement in about 80% of Hep-2 cells and a pyknotic morphology; in the remaining 20% of cells.

All significantly regulated phosphopeptides were compared and many showed a consensus sequence of a clearly proline-dependent phosphorylation sites (S/T-P), which are the target motifs of MAP and cyclin-dependent kinases ([@B1]). This correlates well with earlier observations in which it has been reported that apoptosis induced by TcdB is mediated by MAPK-dependent caspase activation ([@B34]).

The treatment with the enzymatically active TcdB led to generally stronger regulated phosphosites with higher fold changes (Figure [4B](#F4){ref-type="fig"} and Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). Interestingly, the majority of altered p-sites were up-regulated indicating an activation of signaling transduction pathways as a result of treatment with a glucosyltransferase-active toxin. When looking at the top 10 up- and down-regulated proteins it is noticeable that the phosphorylation status of many GTPase effector proteins and GEFs such as Cdc42 effector protein 1/4 and Arhgef2 and Dock5 were altered after TcdB treatment. As expected this was not the case for TcdB~NXN~. Also AP-1 transcription factor phosphorylation sites were highly phosphorylated, which is a downstream factor of p38 and JNK signaling pathways and is activated as a result of stress and apoptosis ([@B24]; [@B37]). In case of TcdB~NXN~ treatment many cytoskeleton and cell proliferation regulators like PPP1R12A and SRSF2 phosphorylation sites were up-regulated. The SRSF2 protein is known to be phosphorylated in response to apoptosis ([@B8]). The 40S ribosomal protein S6 phosphopeptides were strongly downregulated (Table [2](#T2){ref-type="table"}). This ribosomal subunit is involved in cell growth and proliferation by mTOR signaling pathway and is dephosphorylated at growth arrest ([@B22]).

###### 

Top 10 up- and down-regulated phosphosites after 8 h treatment with TcdB~NXN~.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Uniprot ID   Gene name   Protein name                                          Peptide sequence                         log~2~ Ratio TcdB~NXN~/control   *p*-Value   Amino acid    Peptide score
  ------------ ----------- ----------------------------------------------------- ---------------------------------------- -------------------------------- ----------- ------------- ---------------
  Q01130       SRSF2       Serine/arginine-rich splicing factor 2                SK**[S]{.ul}**PPKSPEEEGAVSS              3.27                             2.84E-03    S-208         93.196

  O14974       PPP1R12A    Protein phosphatase 1 regulatory subunit 12A          RLA**[S]{.ul}**TSDIEEK                   2.94                             2.33E-03    S-507         142.95

  Q09666       AHNAK       Neuroblast differentiation-associated protein AHNAK   LK**[S]{.ul}**EDGVEGDLGETQSR             2.92                             2.85E-03    S-135         255.63

  Q8WX93       PALLD       Palladin                                              IA**[S]{.ul}**DEEIQGTK                   2.86                             6.28E-03    S-893         181.75

  O94906       PRPF6       Pre-mRNA-processing factor 6                          LSQVSDSVSGQ**[T]{.ul}**VVDPK             2.85                             1.53E-02    T-266         143.47

  P16989       YBX3        Y-box-binding protein 3                               **[S]{.ul}**VGDGETVEFDVVEGEK             2.75                             1.18E-02    S-102         149.44

  Q8IVT2       MISP        Mitotic interactor and substrate of PLK1              HL**[S]{.ul}**ESSGKPLSTK                 2.75                             3.82E-02    S-471         144.41

  G5E9C8       SOS1        Son of sevenless homolog 1                            SA**[S]{.ul}**VSSISLTK                   2.57                             3.82E-02    S-1119        81.789

  E9PFD7       EGFR        Receptor protein-tyrosine kinase                      ELVEPL**[T]{.ul}**PSGEAPNQALLR           2.36                             1.26E-03    T-648         218.81

  P29966       MARCKS      Myristoylated alanine-rich C-kinase substrate         GEPAAAAAPEAGA**[S]{.ul}**PVEK            2.31                             1.05E-03    S-101         185.3

  P62753       RPS6        40S ribosomal protein S6                              LS**[S]{.ul}**LRAS**[T]{.ul}**SKSESSQK   −2.39                            1.84E-03    S-236;T-241   112.12

  P62753       RPS6        40S ribosomal protein S6                              RL**[SS]{.ul}**LR                        −2.23                            5.54E-04    S-235;S-236   126.16

  P62753       RPS6        40S ribosomal protein S6                              RL**[S]{.ul}**SLR                        −1.97                            4.04E-03    S-235         126.16

  P62753       RPS6        40S ribosomal protein S6                              RLS**[S]{.ul}**LR                        −1.93                            3.41E-02    S-236         126.16

  P62753       RPS6        40S ribosomal protein S6                              RLSSLRA**[S]{.ul}**TSK                   −1.86                            5.35E-03    S-240         125.84

  Q9UQ35       SRRM2       Serine/arginine repetitive matrix protein 2           SSRS**[S]{.ul}**PELTRK                   −1.71                            3.25E-03    S-1694        110.55

  A0A0A0MT60   FKBP15      Peptidyl-prolyl cis-trans isomerase                   SSL**[S]{.ul}**GDEEDELFK                 −1.69                            6.89E-03    S-1189        175.27

  G3V160       CNKSR1      Connector enhancer of kinase suppressor of ras 1      SPSLSLAPL**[S]{.ul}**PR                  −1.62                            1.26E-02    S-49          118.2

  Q92797       SYMPK       Symplekin                                             SPQTLAPVGE\                              −1.62                            2.73E-03    S-1259        111.09
                                                                                 DAMKTP**[S]{.ul}**PAAEDAREPEAK                                                                      

  A0A096LNZ0   AAK1        Uncharacterized protein FLJ45252                      LGGAVPFAPPEV**[S]{.ul}**PEQAK            −1.58                            5.82E-04    S-217         130.37
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Phosphosites with MAP kinase motifs were differently regulated in TcdB and TcdBNXN. These kinases are particular involved in ERK, JNK und p38 signaling pathways ([@B28]). Several proteins belonging to these pathways have been identified in a proteome analysis to be regulated in similar treated cells ([@B16]). Particularly RAF activators and transcription factors, e.g., AP-1 localized downstream of JNK signaling are involved. These pathways regulates apoptotic processes and cell cycle arrest ([@B7], [@B14]). These hypothesis are supported by further studies that provide evidence for a caspase-mediated apoptosis induced by C. difficile toxins ([@B29]; [@B32]; [@B25]). First an activation of inhibitory caspases 8 and 9 is induced with an subsequent activation of known effector caspases 3, 6, and 7 that are involved in the cytotoxic effects induced by C. difficile toxins.

At a first glance these preliminary results suggest signaling pathways to be affected by TcdB or TcdB~NXN~ treatment. Nevertheless, further investigations are necessary to further elaborate and confirm these findings.
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